IceCure Medical (NASDAQ:ICCM) Trading Down 0.4% – Should You Sell?

Posted by MarketBeat News on Dec 20th, 2024

IceCure Medical Ltd (NASDAQ:ICCM – Get Free Report) traded down 0.4% during mid-day trading on Thursday . The stock traded as low as $1.12 and last traded at $1.15. 341,936 shares traded hands during trading, a decline of 40% from the average session volume of 574,286 shares. The stock had previously closed at $1.16.

Analysts Set New Price Targets

A number of research firms have recently commented on ICCM. HC Wainwright restated a “buy” rating and set a $2.50 price objective on shares of IceCure Medical in a report on Wednesday, November 27th. Alliance Global Partners upgraded IceCure Medical to a “strong-buy” rating in a research note on Friday, November 1st.

Get Our Latest Stock Analysis on IceCure Medical

IceCure Medical Price Performance

Want More Great Investing Ideas?

The stock has a market cap of $52.46 million, a PE ratio of -3.97 and a beta of 0.50. The company has a quick ratio of 2.27, a current ratio of 2.67 and a debt-to-equity ratio of 0.02. The company’s fifty day moving average is $0.74 and its 200 day moving average is $0.71.

Hedge Funds Weigh In On IceCure Medical

An institutional investor recently bought a new position in IceCure Medical stock. Renaissance Technologies LLC purchased a new stake in IceCure Medical Ltd (NASDAQ:ICCM – Free Report) in the 2nd quarter, according to its most recent filing with the SEC. The institutional investor purchased 66,400 shares of the company’s stock, valued at approximately $49,000. Renaissance Technologies LLC owned approximately 0.15% of IceCure Medical at the end of the most recent quarter. 0.62% of the stock is currently owned by institutional investors.

About IceCure Medical

(Get Free Report)

IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology.